Form 4: 23andMe CFO Joseph Selsavage Receives 1 Million Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Joseph Selsavage, CFO of 23andMe Holding Co., was granted 1,000,000 restricted stock units (RSUs) that vest quarterly starting August 20, 2024.

Summary

  • On May 21, 2024, Joseph Selsavage, the Chief Financial & Acting Officer of 23andMe Holding Co., was granted 1,000,000 restricted stock units (RSUs).
  • These RSUs vest in equal quarterly installments, beginning on August 20, 2024.
  • The vesting is contingent upon continued service with 23andMe Holding Co. and is subject to the terms of the equity plan and tax withholding obligations.
  • Each RSU represents the right to receive one share of Class A Common Stock of the company.
  • Following the transaction, Selsavage directly owns 2,258,390 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and indicates confidence in the executive's continued service. However, it doesn't provide significant new information about the company's overall performance.

Positives

  • The grant of RSUs aligns the CFO's interests with the long-term success of the company.
  • Continued service requirement encourages retention of key personnel.

Risks

  • The value of the RSUs is dependent on the future performance of 23andMe's Class A Common Stock.
  • If Selsavage leaves the company before the RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Equity grants are a common practice in the tech industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for a CFO role in a company of 23andMe's size and stage.

Comparison to Industry Standards

  • Equity compensation for CFOs in publicly traded companies varies widely based on company size, performance, and industry.
  • Comparable companies in the biotech or personalized medicine space often use a mix of stock options, restricted stock units, and performance-based equity awards.
  • The vesting schedule of 1/8 quarterly installments is a fairly standard approach to ensure continued service over a two-year period.

Stakeholder Impact

  • The RSU grant could have a slightly dilutive effect on existing shareholders.
  • The grant incentivizes the CFO to focus on long-term value creation for shareholders.

Key Dates

DateDescription
05/21/2024Date of the transaction (grant of RSUs)
08/20/2024Commencement date for quarterly vesting of RSUs
05/23/2024Date of signature on the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.